Roche ROP 2.42%increase; green up pointing triangle Holding expects drugs it already has on the market and a trio of medicines due to be launched shortly to deliver sales growth for its pharmaceutical business through the end of the decade, its chief executive said.
The Swiss drugmaker’s on-market pharma portfolio, together with its Gazyva drug for lupus, giredestrant for breast cancer and fenebrutinib for multiple sclerosis, should make up for any hit from generic competition until 2030, Roche Chief Executive Thomas Schinecker said at an event with investors in London on Tuesday.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8